{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:22:31Z","timestamp":1762899751105,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12325-019-00914-9","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T10:58:24Z","timestamp":1552301904000},"page":"798-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia"],"prefix":"10.1007","volume":"36","author":[{"given":"Ju-Ming","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"914_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.2337\/db16-0766","volume":"66","author":"R Unnikrishnan","year":"2017","unstructured":"Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 diabetes: demystifying the global epidemic. Diabetes. 2017;66:1432\u201342.","journal-title":"Diabetes"},{"key":"914_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/dom.13349","volume":"20","author":"E Blind","year":"2018","unstructured":"Blind E, Janssen H, Dunder K, de Graeff PA. The European Medicines Agency\u2019s approval of new medicines for type 2 diabetes. Diabetes Obes Metab. 2018;20:2059\u201363.","journal-title":"Diabetes Obes Metab"},{"key":"914_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s13300-016-0207-6","volume":"7","author":"H Shu","year":"2016","unstructured":"Shu H, Gu LN, Men LC, Lu JM. Lixisenatide improves glycemic control in Asian type 2 diabetic patients inadequately controlled with oral antidiabetic drugs: an individual patient data meta-analysis. Diabetes Ther. 2016;7:777\u201392.","journal-title":"Diabetes Ther."},{"key":"914_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/1471-2458-13-602","volume":"13","author":"LN Ji","year":"2013","unstructured":"Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013;13:602.","journal-title":"BMC Public Health"},{"key":"914_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/nyas.12098","volume":"1281","author":"RC Ma","year":"2013","unstructured":"Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64\u201391.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"914_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1477-7525-8-62","volume":"26","author":"Z Liu","year":"2010","unstructured":"Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010;26(8):62.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"914_CR7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s11892-015-0602-9","volume":"15","author":"D Yabe","year":"2015","unstructured":"Yabe D, Seino Y, Fukushima M, Seino S. \u03b2 cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6):602.","journal-title":"Curr Diab Rep"},{"issue":"Suppl 1","key":"914_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/jdi.12490","volume":"7","author":"Y Seino","year":"2016","unstructured":"Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102\u20139.","journal-title":"J Diabetes Investig"},{"key":"914_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/dmrr.2827","volume":"32","author":"J Weng","year":"2016","unstructured":"Weng J, Ji L, Jia W, et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev. 2016;32:442\u201358.","journal-title":"Diabetes Metab Res Rev"},{"key":"914_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S2213-8587(14)70136-6","volume":"2","author":"W Yang","year":"2014","unstructured":"Yang W, Weng J. Early therapy for type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014;2:992\u20131002.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"914_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s42000-018-0038-0","volume":"17","author":"D Sfairopoulos","year":"2018","unstructured":"Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones (Athens). 2018;17:333\u201350.","journal-title":"Hormones (Athens)"},{"key":"914_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1185\/03007995.2015.1103214","volume":"32","author":"XH Guo","year":"2016","unstructured":"Guo XH. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. Curr Med Res Opin. 2016;32:61\u201376.","journal-title":"Curr Med Res Opin"},{"key":"914_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.regpep.2008.07.003","volume":"151","author":"H Linnebjerg","year":"2008","unstructured":"Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123\u20139.","journal-title":"Regul Pept"},{"key":"914_CR14","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1185\/03007990802418851","volume":"24","author":"RA DeFronzo","year":"2008","unstructured":"DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943\u201352.","journal-title":"Curr Med Res Opin"},{"key":"914_CR15","doi-asserted-by":"publisher","first-page":"E846","DOI":"10.1152\/ajpendo.00030.2008","volume":"294","author":"A Cervera","year":"2008","unstructured":"Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294:E846\u201352.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"914_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2337\/dc14-1984","volume":"38","author":"JJ Meier","year":"2015","unstructured":"Meier JJ, Rosenstock J, Hincelin-M\u00e9ry A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38:1263\u201373.","journal-title":"Diabetes Care"},{"key":"914_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/dmrr.2647","volume":"31","author":"RH Becker","year":"2015","unstructured":"Becker RH, Stechl J, Steinstraesser A, Golor G, Pellissier F. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects. Diabetes Metab Res Rev. 2015;31:610\u20138.","journal-title":"Diabetes Metab Res Rev"},{"key":"914_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.regpep.2013.04.001","volume":"185","author":"M Lorenz","year":"2013","unstructured":"Lorenz M, Pfeiffer C, Steinstr\u00e4sser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes\u2013relationship to postprandial glycemia. Regul Pept. 2013;185:1\u20138.","journal-title":"Regul Pept"},{"key":"914_CR19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/dom.12935","volume":"19","author":"DH Raalte van","year":"2017","unstructured":"van Raalte DH, Verchere CB. Improving glycaemic control in type 2 diabetes: stimulate insulin secretion or provide beta-cell rest? Diabetes Obes Metab. 2017;19:1205\u201313.","journal-title":"Diabetes Obes Metab"},{"key":"914_CR20","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1210\/jc.2002-021545","volume":"88","author":"OG Kolterman","year":"2003","unstructured":"Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3082\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"914_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1530\/EJE-16-0286","volume":"175","author":"DH Raalte van","year":"2016","unstructured":"van Raalte DH, Bunck MC, Smits MM, et al. Exenatide improves \u03b2-cell function up to 3\u00a0years of treatment in patients with type 2 diabetes: a randomised controlled trial. Eur J Endocrinol. 2016;175:345\u201352.","journal-title":"Eur J Endocrinol"},{"key":"914_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1573399812666151223093841","volume":"12","author":"SR Drab","year":"2016","unstructured":"Drab SR. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy. Curr Diabetes Rev. 2016;12:403\u201313.","journal-title":"Curr Diabetes Rev"},{"key":"914_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4093\/dmj.2017.41.6.423","volume":"41","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Park SO, Ko SH, et al. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: a position statement of the Korean Diabetes Association. Diabetes Metab J. 2017;41:423\u20139.","journal-title":"Diabetes Metab J"},{"key":"914_CR24","doi-asserted-by":"publisher","unstructured":"Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig. 2018. \n                    https:\/\/doi.org\/10.1111\/jdi.12810\n                    \n                  .","DOI":"10.1111\/jdi.12810"},{"issue":"1","key":"914_CR25","first-page":"4","volume":"10","author":"Chinese Diabetes Society","year":"2018","unstructured":"Chinese Diabetes Society. Chinese guideline for the prevention and treatment of type 2 diabetes mellitus (2017 edition). Chin J Diabetes Mellitus. 2018;10(1):4\u201367.","journal-title":"Chin J Diabetes Mellitus"},{"key":"914_CR26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/dom.12293","volume":"16","author":"YG Kim","year":"2014","unstructured":"Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"914_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","volume":"56","author":"YG Kim","year":"2013","unstructured":"Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696\u2013708.","journal-title":"Diabetologia"},{"key":"914_CR28","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1345\/aph.1R041","volume":"46","author":"H Park","year":"2012","unstructured":"Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46:1453\u201369.","journal-title":"Ann Pharmacother"},{"key":"914_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/jdi.12305","volume":"6","author":"YM Cho","year":"2015","unstructured":"Cho YM. Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig. 2015;6:495\u2013507.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"914_CR30","doi-asserted-by":"publisher","first-page":"15997","DOI":"10.1038\/s41598-017-16018-9","volume":"7","author":"F Zhang","year":"2017","unstructured":"Zhang F, Tang L, Zhang Y, L\u00fc Q, Tong N. Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight\/obesity: meta-analysis of randomized controlled trials. Sci Rep. 2017;7(1):15997.","journal-title":"Sci Rep"},{"key":"914_CR31","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00125-013-2874-4","volume":"56","author":"RC Ma","year":"2013","unstructured":"Ma RC, Hu C, Tam CH, et al. Genome-wide association study in a Chinese population identifies a susceptibility locus for type 2 diabetes at 7q32 near PAX4. Diabetologia. 2013;56:1291\u2013305.","journal-title":"Diabetologia"},{"key":"914_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/dmrr.1149","volume":"27","author":"JS Wang","year":"2011","unstructured":"Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27:79\u201384.","journal-title":"Diabetes Metab Res Rev"},{"key":"914_CR33","doi-asserted-by":"publisher","first-page":"e3062","DOI":"10.1002\/dmrr.3062","volume":"15","author":"XM Zhang","year":"2018","unstructured":"Zhang XM, Li PF, Hou JN, Ji LN. Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes mellitus inadequately controlled on oral antihyperglycemic medication: pooled analysis of individual patient data. Diabetes Metab Res Rev. 2018;15:e3062.","journal-title":"Diabetes Metab Res Rev"},{"key":"914_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.diabres.2015.12.004","volume":"114","author":"WH Sheu","year":"2016","unstructured":"Sheu WH, Brunell SC, Blase E. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Res Clin Pract. 2016;114:160\u201372.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"914_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13098-016-0151-7","volume":"1","author":"H Seino","year":"2016","unstructured":"Seino H, Onishi Y, Naito Y, Komatsu M. Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2016;1(8):36.","journal-title":"Diabetol Metab Syndr"},{"key":"914_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2879","author":"RM Bergenstal","year":"2017","unstructured":"Bergenstal RM, Strock E, Mazze R, et al. Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: an analysis using continuous glucose monitoring. Diabetes Metab Res Rev. 2017. \n                    https:\/\/doi.org\/10.1002\/dmrr.2879\n                    \n                  .","journal-title":"Diabetes Metab Res Rev"},{"key":"914_CR37","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc16-0985","volume":"40","author":"KJ Lipska","year":"2017","unstructured":"Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care. 2017;40:468\u201375.","journal-title":"Diabetes Care"},{"key":"914_CR38","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","volume":"384","author":"C Eng","year":"2014","unstructured":"Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228\u201334.","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"914_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/14740338.2016.1221402","volume":"15","author":"D Cimmaruta","year":"2016","unstructured":"Cimmaruta D, Maiorino MI, Scavone C, et al. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opin Drug Saf. 2016;15(Suppl. 2):77\u201383.","journal-title":"Expert Opin Drug Saf"},{"key":"914_CR40","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2337\/dc16-1957","volume":"40","author":"MI Maiorino","year":"2017","unstructured":"Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2017;40:614\u201324.","journal-title":"Diabetes Care"},{"key":"914_CR41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","volume":"14","author":"Y Seino","year":"2012","unstructured":"Seino Y, Min KW, Niemoeller E, Takami A, EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14:910\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"914_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/dom.13072","volume":"20","author":"W Yang","year":"2018","unstructured":"Yang W, Min K, Zhou Z, et al. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: the GetGoal-L-C randomized trial. Diabetes Obes Metab. 2018;20:335\u201343.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"914_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4093\/dmj.2017.41.1.69","volume":"41","author":"KH Yoon","year":"2017","unstructured":"Yoon KH, Hardy E, Han J. Exenatide versus insulin lispro added to basal insulin in a subgroup of Korean patients with type 2 diabetes mellitus. Diabetes Metab J. 2017;41(1):69\u201374.","journal-title":"Diabetes Metab J"},{"issue":"10","key":"914_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13098-018-0321-x","volume":"13","author":"T Bo\u017eek","year":"2018","unstructured":"Bo\u017eek T, Bili\u0107-\u0106ur\u010di\u0107 I, Berkovi\u0107 MC, et al. The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study. Diabetol Metab Syndr. 2018;13(10):16.","journal-title":"Diabetol Metab Syndr"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00914-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:17:28Z","timestamp":1583799448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00914-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00914-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"3 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}